The long‐term outcome of patients with polycystic liver disease treated with lanreotide
Authors:
Open Access
- 24 November 2011
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 35 (2) , 266-274
Abstract
Aliment Pharmacol Ther 2012; 35: 266–274Summary: Background Polycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease. Somatostatin analogues, such as lanreotide, reduce polycystic liver volume.Aim To establish long‐term outcome and safety of lanreotide.Methods This was an open‐label, observational extension study of a 6‐month, randomised, placebo‐controlled trial with lanreotide (120 mg/month) in PLD. The length of total treatment was 12 months. Primary endpoint was relative change in liver volume, as determined by CT‐volumetry after 12 months of treatment. We offered patients a CT scan 6 months after stopping lanreotide.Results A total of 41/54 (76%) patients participated in the extension study. Liver volume decreased by 4% (IQR −8% to −1%) after 12 months of treatment. The greatest effect was observed during the first 6 months of treatment (decrease of 4% (IQR −6% to −1%)). Liver volume remained unchanged during the following 6 months. We found that liver volume increased by 4% (IQR 0–6%) 6 months after end of treatment (n = 22).Conclusions Lanreotide reduces liver volume within the first 6 months of treatment and the beneficial effect is maintained in the following 6 months. Stopping results in recurrence of polycystic liver growth. This suggests that continuous use of lanreotide is needed to maintain its effect.Keywords
This publication has 22 references indexed in Scilit:
- Systematic review: the pathophysiology and management of polycystic liver diseaseAlimentary Pharmacology & Therapeutics, 2011
- Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)Alimentary Pharmacology & Therapeutics, 2011
- Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver DiseaseJournal of the American Society of Nephrology, 2010
- Reducing Polycystic Liver Volume in ADPKDClinical Journal of the American Society of Nephrology, 2010
- Polycystic Liver DiseaseAnnals of Surgery, 2009
- The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD)†Hepatology, 2008
- Hepatic Cystogenesis Is Associated with Abnormal Expression and Location of Ion Transporters and Water Channels in an Animal Model of Autosomal Recessive Polycystic Kidney DiseaseThe American Journal of Pathology, 2008
- Evaluation of a Gastrointestinal Symptoms QuestionnaireDigestive Diseases and Sciences, 2006
- Liver transplantation for polycystic liver diseaseLiver Transplantation, 2001
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992